Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ABSI
$2.71
$
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Next Earnings
2026-02-25
Beta
2.122
Average Volume
Market Cap
Last Dividend
CIK
0001672688
ISIN
US00091E1091
CUSIP
00091E109
CEO
Sean McClain
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
156
IPO Date
2021-07-22
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 | VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. | GlobeNewsWire | 2026-02-24 08:00:00 |
| Absci to Participate in Upcoming Investor Conferences | VANCOUVER, Wash. and NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the following upcoming investor conferences: TD Cowen 46 th Annual Health Care Conference (Boston, MA) Fireside chat on Monday, March 2 at 9:10 a.m. | GlobeNewsWire | 2026-02-17 08:00:00 |
| The Genesis Mission Has a 270-Day Timeline – And You’re Already Late | The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits. | Investor Place | 2026-01-27 00:00:00 |
| Absci Corporation (ABSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Absci Corporation (ABSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-14 22:16:00 |
| Absci Corporation (NASDAQ:ABSI) Given Consensus Rating of “Moderate Buy” by Brokerages | Shares of Absci Corporation (NASDAQ: ABSI - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year | Defense World | 2026-01-02 01:23:09 |
| The Genesis Mission Has a 270-Day Timeline – And You’re Already Late | The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits. | Investor Place | 2025-12-20 00:00:00 |
| Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference | VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the upcoming 44th Annual J.P. | GlobeNewsWire | 2025-12-16 08:00:00 |
| Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia Transcript | Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia Transcript | Seeking Alpha | 2025-12-11 16:52:53 |
| Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization | Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo | GlobeNewsWire | 2025-12-11 08:00:00 |
| Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research | Partnership aims to destigmatize androgenetic alopecia and highlight the need for new therapeutic options that address the root cause of disease | GlobeNewsWire | 2025-12-10 08:00:00 |
| ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study | Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals. | Zacks Investment Research | 2025-12-05 11:41:05 |
| Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia | Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational trials for androgenetic alopecia (AGA) and Phase 2 for endometriosis KOL seminar scheduled for December 11 to discuss new human ex vivo data, clinical trial design, and market opportunity in AGA VANCOUVER, Wash. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced that the first healthy volunteers have been dosed in the Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody engineered with Absci's generative AI platform. | GlobeNewsWire | 2025-12-04 08:00:00 |
| 10 AI Stocks Worth Buying Right Now | Artificial intelligence (AI) will reshape industries for decades, making early positioning in focused AI players critical. Smaller AI companies often offer more upside than megacaps that have already priced in the boom. | The Motley Fool | 2025-12-04 05:45:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-01-30 | 2026-01-30 | View Filing |
| SC 13G | 2026-01-30 | 2026-01-30 | View Filing |
| 8-K | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-01 | 2025-12-01 | View Filing |
| SC 13G/A | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-04 | 2025-11-04 | View Filing |
| SC 13G/A | 2025-10-30 | 2025-10-30 | View Filing |
| 4 | 2025-10-14 | 2025-10-14 | View Filing |
| 4 | 2025-10-14 | 2025-10-14 | View Filing |
| 4 | 2025-10-14 | 2025-10-14 | View Filing |
| 4 | 2025-10-14 | 2025-10-14 | View Filing |
| 4 | 2025-09-24 | 2025-09-24 | View Filing |
| 4 | 2025-09-24 | 2025-09-24 | View Filing |
| 4 | 2025-09-02 | 2025-09-02 | View Filing |
| EFFECT | 2025-08-25 | 2025-08-25 | View Filing |
| 424B3 | 2025-08-22 | 2025-08-22 | View Filing |
| 8-K/A | 2025-08-12 | 2025-08-12 | View Filing |
| S-3 | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| SC 13G | 2025-07-29 | 2025-07-29 | View Filing |
| 4 | 2025-07-29 | 2025-07-29 | View Filing |
| 424B5 | 2025-07-25 | 2025-07-25 | View Filing |
| 8-K | 2025-07-25 | 2025-07-25 | View Filing |
| 424B5 | 2025-07-24 | 2025-07-24 | View Filing |
| SC 13G/A | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-09 | 2025-07-09 | View Filing |
| 3 | 2025-07-09 | 2025-07-09 | View Filing |
| 8-K | 2025-07-08 | 2025-07-08 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 8-K | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-02 | 2025-06-02 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13G/A | 2025-05-14 | 2025-05-14 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| SC 13G/A | 2025-05-12 | 2025-05-12 | View Filing |
| SC 13D/A | 2025-04-29 | 2025-04-29 | View Filing |
| ARS | 2025-04-28 | 2025-04-28 | View Filing |
| DEFA14A | 2025-04-28 | 2025-04-28 | View Filing |
| DEF 14A | 2025-04-28 | 2025-04-28 | View Filing |
| 8-K | 2025-04-28 | 2025-04-28 | View Filing |
| 424B3 | 2025-04-11 | 2025-04-11 | View Filing |
| EFFECT | 2025-04-11 | 2025-04-11 | View Filing |
| S-3 | 2025-04-01 | 2025-04-01 | View Filing |
| S-8 | 2025-03-18 | 2025-03-18 | View Filing |
| 10-K | 2025-03-18 | 2025-03-18 | View Filing |
| 8-K | 2025-03-18 | 2025-03-18 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| SC 13G/A | 2025-02-19 | 2025-02-19 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 8-K | 2025-01-15 | 2025-01-15 | View Filing |
| SC 13G | 2025-01-10 | 2025-01-10 | View Filing |
| 4 | 2024-12-09 | 2024-12-09 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| SC 13G | 2024-10-18 | 2024-10-18 | View Filing |
| 4 | 2024-10-16 | 2024-10-16 | View Filing |
| 4 | 2024-10-16 | 2024-10-16 | View Filing |
| 4 | 2024-10-16 | 2024-10-16 | View Filing |
| 4 | 2024-10-16 | 2024-10-16 | View Filing |
| 4 | 2024-09-04 | 2024-09-04 | View Filing |
| 8-K | 2024-09-04 | 2024-09-04 | View Filing |
| 10-Q | 2024-08-14 | 2024-08-14 | View Filing |
| 8-K | 2024-08-14 | 2024-08-14 | View Filing |
| 4 | 2024-07-03 | 2024-07-03 | View Filing |
| 3 | 2024-07-03 | 2024-07-03 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 8-K | 2024-06-14 | 2024-06-14 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Directional Movement Index Strategy | 23.03% | 0.99 | 259 | 0.02 | 0.07 | 37.77 |
| Volume Weighted Momentum Strategy | 18.67% | 1 | 1 | 0.01 | 0.04 | 33.41 |
| Choppiness Index Strategy | 16.20% | 1 | 903 | 0.01 | 0.03 | 30.94 |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxxx | x | x | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | x |
| xxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |